CD68 and non-small cell lung carcinoma: Previous studies have identified CD204+ TAMs as prognostic markers in non-small cell lung carcinoma (NSCLC), especially in lung adenocarcinoma [25], and the combined use of CD47 and CD68 was reported to predict the survival of eastern-Asian patients with NSCLC [26].